

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10524300
	Filing Date		2005-08-29
	First Named Inventor	Jingwu Z. Zang	
	Art Unit	1644	
	Examiner Name	DIBRINO, MARIANNE NMN	
Attorney Docket Number		050989.0201.01USCP	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	WO 03/024393 PCT/US02/20074	WO WO		2003-03-27 2002-03-12	Opexa Pharmaceuticals, Inc.		<input type="checkbox"/>
	2	WO 99/13904	WO		1999-03-25	University of Southern California		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS							
---------------------------------	--	--	--	--	--	--	--

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10524300
Filing Date	2005-08-29
First Named Inventor	Jingwu Z. Zang
Art Unit	1644
Examiner Name	DIBRINO, MARIANNE NMN
Attorney Docket Number	050989.0201.01USCP

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	CORREALE, J et al. Isolation and characterization of autoreactive proteolipid protein specific T-cell clones from multiple sclerosis patients. Neurology, 1995;45:1370-8.	<input type="checkbox"/>
	2	WARREN, KG et al. Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. Ann Neurol, 1994;35:280-9.	<input type="checkbox"/>
	3	OLSSON, T et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest, 1990;86:981-5.	<input type="checkbox"/>
	4	ZHANG, J et al. T-cell vaccination in autoimmune diseases. Human Immunology, 1993;38:87-96.	<input type="checkbox"/>
	5	ACHIRON, A. T-cell vaccination in multiple sclerosis. Autoimmunity Reviews, 2004;3:25-32.	<input type="checkbox"/>
	6	ACHIRON, A et al. T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clinical Immunology, 2004;113:155-160.	<input type="checkbox"/>
	7	BEN-NUN, A. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced diseases. Journal Neurol, 1996;243(1):S14-S22.	<input type="checkbox"/>
	8	BEN-NUN, A. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur Journal Immunol, 1981;11:195-9.	<input type="checkbox"/>
	9	BEN-NUN, A. Vaccination against autoimmune encephalomyelitis with T lymphocyte line cells reactive against myelin basic protein. Nature, 1981;292(5919):60-1.	<input type="checkbox"/>
	10	HELLINGS, N et al. T cell vaccination in multiple sclerosis: update on clinical application and mode of action. Autoimmunity Reviews, 2004;3:267-75.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10524300
Filing Date	2005-08-29
First Named Inventor	Jingwu Z. Zang
Art Unit	1644
Examiner Name	DIBRINO, MARIANNE NMN
Attorney Docket Number	050989.0201.01USCP

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Marianne DiBrino/	Date Considered	01/07/2010
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.